Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

The tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) have shown anti-tumor activity in the treatment of non-small cell lung cancer (NSCLC). Dramatic and durable responses have occurred in NSCLC tumors with mutations in the tyrosine kinase domain of the epidermal growth factor re...

Full description

Saved in:
Bibliographic Details
Main Authors: Ji, Hongbin, Zhao, Xiaojun, Yuza, Yuki, Shimamura, Takeshi, Li, Danan, Protopopov, Alexei, Jung, Boonim L., McNamara, Kate, Xia, Huili, Glatt, Karen A., Thomas, Roman K., Sasaki, Hidefumi, Horner, James W., Eck, Michael, Mitchell, Albert, Sun, Yangping, Al-Hashem, Ruqayyah, Bronson, Roderick T., Rabindran, Sridhar K., Discafani, Carolyn M., Maher, Elizabeth, Shapiro, Geoffrey I., Meyerson, Matthew, Wong, Kwok-Kin
Format: Artigo
Language:Inglês
Published: National Academy of Sciences 2006
Subjects:
Biological Sciences
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1456806/
https://ncbi.nlm.nih.gov/pubmed/16672372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0510284103
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items